Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.50 |
| ▸ | BCHE | P06276 | 2/20 | 0.46 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | PLG | P00747 | 1/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.44 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.44 |
| ▸ | C1S | P09871 | 1/20 | 0.44 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.44 |
| ▸ | CFD | P00746 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | NOS1 | P29475 | 1/20 | 0.44 |
| ▸ | NOS2 | P35228 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29818997 | 0.88 | TAAR1 (0.55) | MAOBBCHECYP4F2CYP4A11F2 | |
| SCHEMBL2204444 | 0.88 | TAAR1 (0.55) | MAOBBCHECYP4F2CYP4A11F2 | |
| SCHEMBL2570826 | 0.87 | TAAR1 (0.49) | MAOBCFD | |
| SCHEMBL2204754 | 0.87 | CYP4F2 (0.50) | MAOBBCHECYP4F2CYP4A11 | |
| SCHEMBL29818962 | 0.84 | TAAR1 (0.55) | MAOB | |
| SCHEMBL2207600 | 0.84 | TAAR1 (0.55) | MAOB | |
| SCHEMBL2573622 | 0.84 | TAAR1 (0.49) | MAOBCFD | |
| SCHEMBL2204637 | 0.84 | CYP4F2 (0.50) | MAOBBCHECYP4F2CYP4A11 | |
| SCHEMBL538599 | 0.83 | MAOB (0.70) | MAOBBCHECYP4F2CYP4A11NOS1 | |
| SCHEMBL30207536 | 0.83 | MAOB (0.70) | MAOBBCHECYP4F2CYP4A11NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1698635-B1 | BENZIMIDAZOLE DERIVATIVES AND MEDICAL USES THEREOF | KISSEI PHARMACEUTICAL (JP) | 2011-12-14 | — | — | EP | disclosed |
| US-7547680-B2 | Benzimidazole derivatives and medical uses thereof | KISSEI PHARMACEUTICALS, CO., LTD. (JP) | 2009-06-16 | — | — | US | disclosed |
| US-20080038242-A1 | Benzimidazole derivatives and medical uses thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-02-14 | — | — | US | disclosed |
| EP-1698635-A1 | BENZIMIDAZOLE DERIVATIVES AND MEDICAL USES THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2006-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080038242-A1 | Benzimidazole derivatives and medical uses thereof | SLCO1B3, SLCO2A1, SLCO2B1 | MAOB 725/4885BCHE 1689/4885CYP4F2 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.